NICE final guidance recommends Sanofi's Cerdelga for Type I Gaucher's

Last month, the U.K.'s NICE issued final guidance recommending the use of Cerdelga eliglustat from the Sanofi Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat Type I Gaucher’s disease in adults who are cytochrome P450 2D6 (CYP2D6) poor, intermediate or extensive metabolizers. The European Commission approved the drug for the indication in 2015.

NICE said the list price is £342 ($447) per capsule. Intermediate or extensive metabolizers would pay an expected annual drug cost per person of about £250,000 ($326,825) based on additional capsules required compared to poor metabolizers, who would pay an expected cost of about £125,000 ($163,413). NICE said that Sanofi agreed to price Cerdelga at an undisclosed discount under a patient access scheme...